Skovronsky Daniel
SEC CIK 1741474 · EDGAR
BoughtSold
Most active insiders at ILMN, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Meister Keith A. | Dir | — | $591.13M |
| 2 | Davies Scott M | CLO | — | $531.3K |
| 3 | Leckman Patricia | SVP, CHRO | — | $529.7K |
| 4 | Wedel Christensen Jakob | SVP, Strategy, Corp Development | — | $366.1K |
| 5 | Ericksen Scott D | VP, CAO | — | $305.1K |
| 6 | Gottlieb Scott | Dir | $84.6K | — |
| 7 | Sullivan Michael C | Chief Commercial Off | — | — |
| 8 | Barnard Steven | SVP, CTO | — | — |
| 9 | Pegels Kevin Carl | Chief of Gbl Ops | — | — |
| 10 | Dhingra Ankur | SVP, CFO | — | — |
| 12 | Skovronsky Daniel | Dir | — | — |
Transactions 27
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-23 18:01 | 2026-06-16 | ILMN | ILLUMINA, INC. | Skovronsky Daniel | Dir | A - Grant | $164.28 | +1,674 | 1,674 | New | +$275.0K | |
| 2026-06-05 16:25 | 2026-06-04 | MYGN | MYRIAD GENETICS INC | Skovronsky Daniel | Dir | A - Grant | $0.00 | +59.7K | 195.5K | +44% | $0 | |
| 2026-02-11 | 2026-02-09 | LLY | Lilly (Eli) | Skovronsky Daniel | EVP, CS, PO, Pres. LRL | A - Grant | $1,044.67 | +15.5K | 160.1K | +11% | +$16.24M | |
| D | 2026-02-03 | 2026-02-01 | LLY | Lilly (Eli) | Skovronsky Daniel | EVP, CS, PO, Pres. LRL | M - OptEx | $0.00 | +12.7K | 150.2K | +9% | $0 |
| D | 2026-02-03 | 2026-02-01 | LLY | Lilly (Eli) | Skovronsky Daniel | EVP, CS, PO, Pres. LRL | F - Tax | $1,037.15 | -5,641 | 144.5K | -4% | -$5.85M |
| 2025-11-10 | 2025-11-10 | LLY | Lilly (Eli) | Skovronsky Daniel | EVP, CS, PO, Pres. LRL | G - Gift | $0.00 | -179 | 137.5K | -0.1% | $0 | |
| 2025-08-12 | 2025-08-12 | LLY | Lilly (Eli) | Skovronsky Daniel | EVP, CSO, Pres. LRL, LLY Imm | P - Purchase | $634.41 | +1,000 | 137.7K | +0.7% | +$634.4K | |
| 2025-06-06 | 2025-06-05 | MYGN | MYRIAD GENETICS INC | Skovronsky Daniel | Dir | A - Grant | $0.00 | +49.8K | 135.8K | +58% | $0 | |
| DM | 2025-02-12 | 2025-02-10 | LLY | Lilly (Eli) | Skovronsky Daniel | EVP, CSO, Pres. LRL, LLY Imm | S - Sale | $863.21 | -5,000 | 118.6K | -4% | -$4.32M |
| D | 2025-02-12 | 2025-02-10 | LLY | Lilly (Eli) | Skovronsky Daniel | EVP, CSO, Pres. LRL, LLY Imm | A - Grant | $868.88 | +18.8K | 136.7K | +16% | +$16.31M |
| D | 2025-02-04 | 2025-02-01 | LLY | Lilly (Eli) | Skovronsky Daniel | EVP, CSO, Pres. LRL, LLY Imm | F - Tax | $811.08 | -4,004 | 122.9K | -3% | -$3.25M |
| D | 2025-02-04 | 2025-02-01 | LLY | Lilly (Eli) | Skovronsky Daniel | EVP, CSO, Pres. LRL, LLY Imm | M - OptEx | $0.00 | +8,989 | 126.9K | +8% | $0 |
| M | 2024-09-12 | 2024-09-10+ | LLY | Lilly (Eli) | Skovronsky Daniel | EVP, CSO, Pres. LRL, LLY Imm | G - Gift | $0.00 | -5,835 | 117.9K | -5% | $0 |
| 2024-06-10 | 2024-06-06 | MYGN | MYRIAD GENETICS INC | Skovronsky Daniel | Dir | A - Grant | $0.00 | +15.7K | 86.0K | +22% | $0 | |
| D | 2024-02-14 | 2024-02-12 | LLY | Lilly (Eli) | Skovronsky Daniel | EVP, CSO, Pres. LRL, LLY Imm | A - Grant | $737.26 | +12.9K | 123.7K | +12% | +$9.52M |
| D | 2024-02-02 | 2024-02-01 | LLY | Lilly (Eli) | Skovronsky Daniel | EVP, CSO, Pres. LRL, LLY Imm | F - Tax | $645.61 | -4,434 | 110.8K | -4% | -$2.86M |
| D | 2024-02-02 | 2024-02-01 | LLY | Lilly (Eli) | Skovronsky Daniel | EVP, CSO, Pres. LRL, LLY Imm | M - OptEx | $0.00 | +9,941 | 115.3K | +9% | $0 |
| 2023-11-13 | 2023-11-10 | LLY | Lilly (Eli) | Skovronsky Daniel | EVP, Pres, CS, MO, LRL | G - Gift | $0.00 | -17 | 105.3K | -0.0% | $0 | |
| 2023-08-11 | 2023-08-10 | LLY | Lilly (Eli) | Skovronsky Daniel | EVP, Pres, CS, MO, LRL | G - Gift | $0.00 | -249 | 105.3K | -0.2% | $0 | |
| 2023-06-02 | 2023-06-01 | MYGN | MYRIAD GENETICS INC | Skovronsky Daniel | Dir | A - Grant | $0.00 | +15.2K | 70.3K | +27% | $0 | |
| D | 2023-02-14 | 2023-02-10 | LLY | Lilly (Eli) | Skovronsky Daniel | EVP, Pres, CS, MO, LRL | A - Grant | $345.12 | +18.4K | 105.6K | +21% | +$6.35M |
| D | 2023-02-03 | 2023-02-01 | LLY | Lilly (Eli) | Skovronsky Daniel | EVP, Pres, CS, MO, LRL | F - Tax | $344.15 | -7,035 | 87.2K | -7% | -$2.42M |
| D | 2023-02-03 | 2023-02-01 | LLY | Lilly (Eli) | Skovronsky Daniel | EVP, Pres, CS, MO, LRL | M - OptEx | $0.00 | +15.7K | 94.2K | +20% | $0 |
| 2022-06-03 | 2022-06-02 | MYGN | MYRIAD GENETICS INC | Skovronsky Daniel | Dir | A - Grant | $0.00 | +17.3K | 55.2K | +46% | $0 | |
| D | 2022-02-11 | 2022-02-09 | LLY | Lilly (Eli) | Skovronsky Daniel | SVP, CS, MO, Pres. LRL | A - Grant | $243.27 | +22.6K | 78.6K | +40% | +$5.49M |
| D | 2022-02-03 | 2022-02-01 | LLY | Lilly (Eli) | Skovronsky Daniel | SVP, CS, MO, Pres. LRL | M - OptEx | $0.00 | +18.7K | 64.4K | +41% | $0 |
| D | 2022-02-03 | 2022-02-01 | LLY | Lilly (Eli) | Skovronsky Daniel | SVP, CS, MO, Pres. LRL | F - Tax | $245.39 | -8,437 | 56.0K | -13% | -$2.07M |
Purchase Sale Sale after option exercise All abbreviations